Evidence map›Paper›PMID 33589528›Full record

ArticleJournal for immunotherapy of cancer2021

Intratumoral CXCL13

Siyuan Dai, Han Zeng, Zhaopei Liu, Kaifeng Jin, Wenbin Jiang, Zewei Wang, Zhiyuan Lin, Ying Xiong, Jiajun Wang, Yuan Chang and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 158 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
158citing papers in PubMed, 1 pooled it
15.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

158 citing papers in PubMed, 1 synthesis or guideline pooled it, 196 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

98 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 1 country.

Siyuan Dai *Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Han Zeng *Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Zhaopei Liu *Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Kaifeng Jin *Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Wenbin JiangDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Zewei WangDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhiyuan LinDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Ying XiongDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jiajun WangDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yuan ChangDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Qi BaiDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yu XiaDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Li LiuDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yu ZhuDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Le XuDepartment of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yang QuDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China jjxufdu@fudan.edu.cn yqu10@fudan.edu.cn guo.jianming@zs-hospital.sh.cn.
Jianming GuoDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China jjxufdu@fudan.edu.cn yqu10@fudan.edu.cn guo.jianming@zs-hospital.sh.cn.
Jiejie XuDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China jjxufdu@fudan.edu.cn yqu10@fudan.edu.cn guo.jianming@zs-hospital.sh.cn.ORCID 0000-0001-7431-9063
Sun Yat-sen University · CNFudan University · CNFudan University Shanghai Cancer Center · CNShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChemokine (C-X-C motif) ligand 13 (CXCL13) was known as a selective chemotaxis for B cells, a product of follicular helper CD4

methodsWe analyzed prognostic value and immune contexture that associated with CXCL13

resultsIntratumoral CXCL13

conclusionsIntratumoral CXCL13

Indexed as

Tumor EscapeTumor MicroenvironmentBiomarkers, TumorCarcinoma, Renal CellCD8-Positive T-LymphocytesChemokine CXCL13HumansKidney NeoplasmsLymphocytes, Tumor-InfiltratingPrognosisRetrospective StudiesBiomarkers, TumorChemokine CXCL13CXCL13 protein, humanCD8-positive T-lymphocytesimmune evasionimmunotherapykidney neoplasmstumor microenvironment

Identifiers

PMID33589528
PMCPMC7887366
OpenAlexW3130943467

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.